CLDN4 and carcinoma: Immunostaining of 52 effusions and 23 of the 27 primary carcinomas (4 unsatisfactory reactions) for claudin-4 showed its presence in tumor cells in 51/52 effusions and 20/23 primary carcinomas (Figures 4(f)–4(i)).